Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06757010 · ClinicalTrials.gov registry record · Phase 2
A Study of NE3107 in Early Parkinson's
A Phase 2 study of Parkinsons Disease (PD), sponsored by BioVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06757010: Recruiting Phase 2 study of Parkinsons Disease (PD), sponsored by BioVie.
NCT06757010 is a Phase 2 study of Parkinsons Disease (PD) that is actively recruiting participants, run by BioVie. The registered enrollment target is 60 participants, below the 116-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06757010, a Phase 2 study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by BioVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months
Primary Outcome
A unitless inflammatory biomarker calculated by dividing the absolute peripheral blood monocyte count by the absolute peripheral blood lymphocyte count, using values derived from clinical hematology (complete blood count with differential)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NE3107
Study Locations (4)
Michigan
- Quest Research Institute - Farmington Hills
New York
- Dent Neurologic - Amherst
North Carolina
- Science 37 (Nationwide Site) - Morrisville
Ohio
- NeuroScience Research Center, LLC - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2026-01-02 |
| Phase | Phase 2 |
What NCT06757010 shows while recruiting
NCT06757010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 116-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06757010 reports a single indexed study location in Michigan, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06757010 about?
NCT06757010 is a clinical study titled "A Study of NE3107 in Early Parkinson's". The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any fo...
What is the current status of trial NCT06757010?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-26. Estimated completion is 2026-01-02.
What conditions does trial NCT06757010 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD).
What interventions are being tested in trial NCT06757010?
The interventions under investigation include: Placebo (DRUG), NE3107 (DRUG).
Who is sponsoring clinical trial NCT06757010?
This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06757010 being conducted?
This trial has 4 study locations across Michigan, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06757010's enrollment target sits among peer trials
60 14th of 19 higher than 6 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
RECRUITING · Phase 2
-
A Study of Buntanetap in Participants With PD
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI